ASCO GU 2019 Bladder Cancer

Viewing 1-20 of 26 articles

ASCO GU 2019: Phase II Trial of Pembrolizumab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to BCG

ASCO GU 2019: PIVOT-02 Study of NKTR-214 with Nivolumab in Metastatic Urothelial Carcinoma

ASCO GU 2019: Gemcitabine-Carboplatin versus Gemcitabine-Oxaliplatin In Cisplatin Un-Fit Advanced Urothelial Carcinoma: Randomized Phase II Study-COACH Study

ASCO GU 2019: CheckMate 9UT - Nivolumab or Nivo Plus BMS-986205 with or without Intravesical Bacillus Calmette-Guerin in BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer

ASCO GU 2019: POTOMAC Study - Durvalumab and BCG versus BCG Alone in High-risk, BCG-Naïve Non Muscle-Invasive Bladder Cancer

ASCO GU 2019: Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

ASCO GU 2019: Ramucirumab Exposure-Response Relationship in RANGE: Trial in Advanced Platinum-Refractory Urothelial Carcinoma

ASCO GU 2019: Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma - AMBASSADOR versus Observation

ASCO GU 2019: A Phase III, Randomized, Open-label, Multicenter, Global Study of Durvalumab and BCG versus BCG Alone in High-risk, BCG-naïve Non-muscle-invasive Bladder Cancer Patients - POTOMAC

ASCO GU 2019: ATLAS: A Phase II Open-Label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

ASCO GU 2019: Perioperative Immunotherapy in Urothelial Carcinoma: State of Existing Evidence

ASCO GU 2019: Updated Results of Keynote 057: Pembrolizumab for Patients with High-risk Nonmuscle Invasive Bladder Cancer Unresponsive to BCG

ASCO GU 2019: Randomized Phase III Trial of Adjuvant Sequential Chemotherapy plus Radiotherapy versus Adjuvant Radiotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy: Urothelial Carcinoma Subgroup Analysis.

ASCO GU 2019: Sacituzumab Govitecan (IMMU-132) in Patients with Previously Treated Metastatic Urothelial Cancer

ASCO GU 2019: Challenges of Therapy in Upper-Tract Urothelial Carcinoma

ASCO GU 2019: Trimodality Therapy is the Best Option for Muscle-Invasive Bladder Cancer

ASCO GU 2019: Interim Analysis of Ibrutinib Plus Paclitaxel for Patients with Metastatic Urothelial Carcinoma Previously Treated with Platinum-Based Chemotherapy

ASCO GU 2019: Fierce-21: Phase II Study of Vofatamab, a Selective Inhibitor of FGFR3, as Salvage Therapy in Metastatic Urothelial Carcinoma

ASCO GU 2019: Radical Cystectomy is the Best Option for Muscle-Invasive Bladder Cancer

ASCO GU 2019: Multimodality Treatment in Challenging Cases of Urothelial Carcinoma: Case Panel Discussion

1
2